APA

Pivot X., Mansi L., Chaigneau L., Montcuquet P., Thiery-Vuillemin A., Bazan F., Dobi E., Sautiere J. L., Rigenbach F., Algros M. P., Butler S., Jamshidian F., Febbo P., Svedman C., Paget-Bailly S., Bonnetain F. & Villanueva C. (20160425). In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?. : The oncologist.

Chicago

Pivot Xavier, Mansi Laura, Chaigneau Loic, Montcuquet Philippe, Thiery-Vuillemin Antoine, Bazan Fernando, Dobi Erion, Sautiere Jean L, Rigenbach Frederic, Algros Marie P, Butler Steve, Jamshidian Farid, Febbo Phillip, Svedman Christer, Paget-Bailly Sophie, Bonnetain Franck and Villanueva Christian. 20160425. In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?. : The oncologist.

Harvard

Pivot X., Mansi L., Chaigneau L., Montcuquet P., Thiery-Vuillemin A., Bazan F., Dobi E., Sautiere J. L., Rigenbach F., Algros M. P., Butler S., Jamshidian F., Febbo P., Svedman C., Paget-Bailly S., Bonnetain F. and Villanueva C. (20160425). In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?. : The oncologist.

MLA

Pivot Xavier, Mansi Laura, Chaigneau Loic, Montcuquet Philippe, Thiery-Vuillemin Antoine, Bazan Fernando, Dobi Erion, Sautiere Jean L, Rigenbach Frederic, Algros Marie P, Butler Steve, Jamshidian Farid, Febbo Phillip, Svedman Christer, Paget-Bailly Sophie, Bonnetain Franck and Villanueva Christian. In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?. : The oncologist. 20160425.